Main

processing priority

4

site type

0 (generic, awaiting analysis)

review version

11

html import

20 (imported)

Events

first seen date

2024-03-18 08:46:17

expired found date

-

created at

2024-06-05 23:53:04

updated at

2025-03-02 04:41:17

Domain name statistics

length

21

crc

57694

tld

2211

nm parts

0

nm random digits

0

nm rare letters

0

Connections

is subdomain of id

-

previous id

0

replaced with id

0

related id

-

dns primary id

79406567

dns alternative id

147882186

lifecycle status

0 (unclassified, or currently active)

Subdomains and pages

deleted subdomains

0

page imported products

0

page imported random

0

page imported parking

0

Error counters

count skipped due to recent timeouts on the same server IP

0

count content received but rejected due to 11-799

0

count dns errors

0

count cert errors

0

count timeouts

0

count http 429

0

count http 404

0

count http 403

0

count http 5xx

0

next operation date

-

Server

server bits

server ip

-

Mainpage statistics

mp import status

20

mp rejected date

-

mp saved date

-

mp size orig

168486

mp size raw text

11004

mp inner links count

0

mp inner links status

1 (no links)

Open Graph

title

Biosimilars: A global roadmap for policy sustainability

description

image

site name

author

updated

2025-12-16 08:50:26

raw text

Biosimilars Download The Executive Summary Share this Page Biosimilars: A global roadmap for policy sustainability Why identifying sustainable biosimilar policies and creating actionable policy recommendations benefits an international market. Policies Around the World Read the Full Report Organon commissioned an independent analysis in partnership with Charles River Associates to work with a group of national and international biosimilar experts to identify the optimal, sustainable biosimilar policies and to develop actionable policy recommendations to improve biosimilar sustainability for a wide set of countries. What is a Biosimilar? A biosimilar is a biologic medicine that has been developed to be highly similar to an already approved biologic, or reference biologic. Biologics are complex in structure and generally expensive to manufacture. A biosimilar must go through a rigorous approval process to demonstrate there are no clinically meaningful differences in saf...

Text analysis

redirect type

0 (-)

block type

0 (no issues)

detected language

1 (English)

category id

Medycyna (36)

index version

2025110801

spam phrases

0

Text statistics

text nonlatin

0

text cyrillic

0

text characters

9082

text words

1426

text unique words

438

text lines

190

text sentences

26

text paragraphs

10

text words per sentence

54

text matched phrases

12

text matched dictionaries

4

RSS

rss path

rss status

3 (priority 3 already searched, no matches found)

rss found date

-

rss size orig

0

rss items

0

rss spam phrases

0

rss detected language

0 (awaiting analysis)

inbefore feed id

-

inbefore status

0 (new)

Sitemap

sitemap path

sitemap status

1 (priority 1 already searched, no matches found)

sitemap review version

1

sitemap urls count

0

sitemap urls adult

0

sitemap filtered products

0

sitemap filtered videos

0

sitemap found date

-

sitemap process date

-

sitemap first import date

-

sitemap last import date

-